MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.00
-0.78
-1.12%
After Hours: 69.00 0 0.00% 17:29 09/24 EDT
OPEN
69.69
PREV CLOSE
69.78
HIGH
70.14
LOW
68.62
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
101.47
52 WEEK LOW
68.62
MARKET CAP
15.24B
P/E (TTM)
45.16
1D
5D
1M
3M
1Y
5Y
Expert Ratings For Incyte
Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:INCY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the u...
Benzinga · 1d ago
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
Benzinga · 2d ago
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
Zacks.com · 2d ago
Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $80
Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $85 to $80.
Benzinga · 2d ago
Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte For Tafasitamab And Pemigatinib In Latin America
Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International
Benzinga · 2d ago
BRIEF-Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte
reuters.com · 2d ago
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàr...
GlobeNewswire · 2d ago
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $86
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $91 to $86.
Benzinga · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INCY. Analyze the recent business situations of Incyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INCY stock price target is 101.27 with a high estimate of 134.00 and a low estimate of 66.00.
EPS
Institutional Holdings
Institutions: 781
Institutional Holdings: 220.54M
% Owned: 99.87%
Shares Outstanding: 220.84M
TypeInstitutionsShares
Increased
186
14.17M
New
64
1.11M
Decreased
173
11.35M
Sold Out
27
1.90M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Herve Hoppenot
Chief Financial Officer/Executive Vice President
Christiana Stamoulis
Executive Vice President/Chief Scientific Officer
Dashyant Dhanak
Executive Vice President/General Counsel
Maria Pasquale
Executive Vice President/General Manager
Jonathan Dickinson
Executive Vice President/Director of Human Resources
Paula Swain
Executive Vice President
Barry Flannelly
Executive Vice President
Vijay Iyengar
Executive Vice President
Michael Morrissey
Executive Vice President
Steven Stein
Lead Director/Independent Director
Julian Baker
Independent Director
Jean-Jacques Bienaime
Independent Director
Paul Clancy
Independent Director
Wendy Dixon
Independent Director
Jacqualyn Fouse
Independent Director
Edmund Harrigan
Independent Director
Katherine High
No Data
About INCY
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.